US Patent Issued to Mindset Pharma on Aug. 5 for "Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders" (Canadian Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,266, issued on Aug. 5, was assigned to Mindset Pharma Inc. (St-Laurent, Canada).

"Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders" was invented by Abdelmalik Slassi (Mississauga, Canada) and Joseph A. Araujo (Grimsby, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell."

The patent was filed on May 3...